10-Q: Ginkgo Bioworks Reports Q3 Revenue Decline Amid Restructuring

Ginkgo Bioworks Holdings, Inc. reported a significant revenue decrease in Q3 2025 and for the nine months ended September 30, 2025, as it continues its comprehensive restructuring plan.

Summary

• Total revenue for the three months ended September 30, 2025, decreased by $50.2 million to $38.8 million, down from $89.0 million in the prior year period.
• Cell Engineering revenue declined by $45.7 million to $29.4 million for the quarter, primarily due to a $45.4 million non-cash revenue recognition from a terminated Motif contract in Q3 2024.
• Biosecurity revenue decreased by $4.5 million to $9.5 million for the quarter, mainly due to lower revenue from U.S. and foreign government programs.
• Net loss for the three months ended September 30, 2025, increased to $80.8 million, compared to a net loss of $56.4 million in the same period last year.
• For the nine months ended September 30, 2025, total revenue decreased by $46.4 million to $136.8 million, down from $183.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, improved to $232.0 million, compared to a net loss of $439.5 million in the prior year, largely due to the absence of a $47.9 million goodwill impairment charge in 2024 and significant cost reductions.
• Research and development expenses decreased by $154.0 million to $193.6 million for the nine-month period, driven by personnel reductions, facility rationalization, and lower acquired in-process R&D.
• General and administrative expenses decreased by $51.6 million to $137.3 million for the nine-month period, also reflecting personnel and professional fee reductions.
• The company incurred a $21.4 million shortfall in its strategic cloud and AI partnership with Google Cloud as of August 27, 2025, and will make a one-time payment of $14.0 million in Q4 2025 to be released from original minimum annual commitment obligations.
• Cash and cash equivalents, along with marketable securities, totaled $461.9 million as of September 30, 2025, down from $605.7 million (cash, cash equivalents, and restricted cash) at the beginning of the nine-month period.

Sentiment

Score: 4

Explanation: The company faces significant revenue declines in both segments, and while cost-cutting measures have reduced the nine-month net loss, the quarterly net loss worsened. The ongoing restructuring and capital raise through an ATM offering indicate a challenging period of transition and a need for additional funding, despite management's confidence in short-term liquidity.

Positives

• Net loss for the nine months ended September 30, 2025, significantly improved by $207.5 million compared to the prior year, primarily due to cost reductions and the absence of a goodwill impairment charge.
• Operating loss for the nine months ended September 30, 2025, improved by $211.6 million, reflecting effective cost management through restructuring.
• Research and development expenses decreased by $154.0 million for the nine-month period, indicating successful rationalization of development programs and investment prioritization.
• General and administrative expenses decreased by $51.6 million for the nine-month period, demonstrating reduced operational overhead.
• Net cash used in operating activities improved by $153.8 million for the nine-month period, from $277.2 million in 2024 to $123.4 million in 2025.
• The company initiated an At-The-Market (ATM) program, raising $9.4 million in net proceeds through September 30, 2025, enhancing liquidity.

Negatives

• Total revenue decreased significantly by $50.2 million for the three months ended September 30, 2025, and by $46.4 million for the nine months ended September 30, 2025.
• Cell Engineering revenue saw a substantial decline, with non-cash revenue decreasing from $48.0 million in Q3 2024 to zero in Q3 2025, and from $60.1 million to $9.9 million for the nine-month period.
• Biosecurity revenue decreased for both the three and nine-month periods, indicating reduced activity with government programs.
• Net loss for the three months ended September 30, 2025, worsened to $80.8 million from $56.4 million in the prior year quarter.
• The company incurred a $21.4 million shortfall in its Google Cloud partnership commitments and faces a $14.0 million one-time payment in Q4 2025 to amend the agreement.
• Cash and cash equivalents decreased substantially from $561.6 million at December 31, 2024, to $111.1 million at September 30, 2025, although marketable securities were acquired.

Risks

• Intense competition and competitive pressures from other companies worldwide in the industries in which Ginkgo operates.
• Litigation, including securities or shareholder litigation, and the ability to adequately protect Ginkgo's intellectual property rights.
• Rapidly changing technology and extensive competition in the synthetic biology industry that could make products and processes obsolete or non-competitive.
• Ginkgo's ability to convert potential customers from on-premise R&D to outsourced services and reliance on customers to develop, produce, and manufacture products.
• Ginkgo's ability to comply with laws and regulations applicable to its business.
• Market conditions and global and economic factors beyond Ginkgo's control, including U.S. government initiatives in biotechnology, adverse effects from government shutdowns, and the frequency and scale of biological risks.
• The success of Ginkgo's programs, including the efficiency and cost-advantage of cell engineering services, and their potential to contribute revenue, particularly future revenue related to downstream value share.
• Exposure to volatility and liquidity risks inherent in holding equity or convertible debt interests in certain customers.
• Costs required to maintain, expand, and protect Ginkgo's intellectual property.

Future Outlook

Management expects R&D and G&A expenses to either remain consistent or decline in 2025 compared to 2024, reflecting stabilization of operational overhead and the impact of restructuring actions. However, these expenses could increase due to employee incentive programs or additional restructuring costs. The company believes its current liquidity of $461.9 million (cash, cash equivalents, and marketable securities) will be sufficient to fund projected operations for at least the next 12 months.

Management Comments

• Management is focused on improving the company's platform for programming cells to enable customers to leverage biology for impactful products across various industries.
• The company is actively managing its restructuring plan, which includes workforce reductions and facility consolidations, to reduce operational expenditures.
• Management is strategically approaching inorganic growth initiatives, including mergers, acquisitions, and other inorganic growth initiatives, while maintaining a focus on cost control.

Industry Context

The company operates in the synthetic biology industry, characterized by intense competition and rapidly changing technology. It is leveraging advances in machine learning and computational techniques to improve cell programming. The biosecurity segment aims to build a global immune system for biological threats, aligning with increasing government focus on biotechnology and AI in defense and healthcare sectors.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company does not believe any pending litigation to be material, or that the outcome of any such pending litigation would have a material adverse effect on its results of operations, cash flows, or financial condition.

Related Party Transactions

• In February 2025, the company and Motif FoodWorks, Inc. mutually agreed to terminate Motif's sublease, with Motif paying a $1.6 million termination fee.
• In March 2025, the company and BiomEdit, Inc. mutually terminated certain agreements, leading to the recognition of $7.5 million in deferred revenue. BiomEdit is no longer considered a significant related party due to a reduction in the company's equity ownership interest.

Stakeholder Impact

• Shareholders may experience continued volatility due to declining revenue, ongoing restructuring, and the potential for further dilution from the ATM offering.
• Employees are impacted by ongoing workforce reductions as part of the restructuring plan, which commenced in June 2024 and is expected to be substantially completed in 2025.
• Customers in Cell Engineering and Biosecurity segments may see changes in service offerings and commercial terms, including the removal of downstream value share from certain program types.
• Creditors and investors in marketable debt securities are exposed to the company's financial health, though the company maintains a substantial liquidity position.

Next Steps

• Further workforce reductions are expected for the remainder of 2025, with all reductions expected to be substantially completed in 2025.
• The company plans to continue consolidating certain facilities, with subleasing efforts expected to extend into 2026.
• A one-time payment of $14.0 million is required in the fourth quarter of 2025 to amend the Google Cloud partnership agreement.
• The company is obligated to make non-refundable payments of $5.0 million on April 1, 2026, and $6.0 million on April 1, 2027, to Twist as part of an amended supply agreement.
• The company intends to use net proceeds from the ATM offering for general corporate purposes, including financing operations, technology development, working capital, capital expenditures, and potential acquisitions.

Key Dates

Recommendation

Ginkgo Bioworks is in a transitional phase, marked by significant revenue contraction across both its Cell Engineering and Biosecurity segments. While the company has demonstrated improved cost control, leading to a reduced net loss for the nine-month period (albeit with a worsening quarterly net loss), the core business is shrinking. The ongoing restructuring and the initiation of an At-The-Market offering for capital raise signal continued challenges and a need for funding. For a seasoned investor, the current environment suggests a 'hold' position, awaiting clearer signs of revenue stabilization and a return to sustainable growth, as the current financial performance does not yet warrant a 'buy' despite efforts to right-size the operations.

Keywords

Synthetic Biology, Cell Engineering, Biosecurity, Biotechnology, SEC Filing, 10-Q, Financial Results, Restructuring, R&D Services, Genomic Data, AI Partnership, Google Cloud, ATM Offering, Cash Flow, Net Loss, Revenue